NCT07468838Not yet recruiting
Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
Feasibility Study of Circulating Tumour DNA Analysis in Urine (Urinary cfDNA) as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
The UroDNA study is a feasibility study (RIPH category 3) aimed at evaluating the analysis of circulating tumour DNA in urine (urinary cfDNA) as a non-invasive monitoring tool in patients with prostate or bladder cancer. Urine samples will be collected at different times during the course of treatment to define the optimal conditions for cfDNA collection, extraction and analysis, and to explore the detection of tumour mutation profiles. This study does not involve any experimental treatment. Its objective is to validate the technical and clinical feasibility of a molecular monitoring urine test, which could offer a simple and non-invasive alternative to improve the management of urological cancers.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 9 Mar 2026
- Start date
- May 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Institut Cancerologie de l'Ouest
- Diseases
- Prostate cancer, Bladder cancer
- NCT number
- NCT07468838
What you commit to
- Study type: Observational
- Planned participants: 25
- From May 2026 to the primary completion date, Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cancer in the 5 years prior to entering the trial other than basal cell skin cancer or cervical carcinoma in situ,
Other
- Women who are pregnant, likely to become pregnant or breastfeeding,
- Persons deprived of their liberty, under judicial protection, under guardianship or placed under the authority of a guardian, Inability to undergo medical follow-up for the trial for geographical, social or psychological reasons.
Who the study is looking for
- 1\) Five patients for each of the following cancers :
- Patients with high-risk localised prostate cancer eligible for high-dose radiotherapy, or
- Patients with mHSPC eligible for docetaxel chemotherapy, or
- Patients with mCRPC in second-line treatment eligible for luPSMA treatment, or
- Patients with localised bladder cancer eligible for neoadjuvant chemotherapy or,
- Patients with metastatic bladder cancer eligible for enfortumab vedotin (EV) plus pembrolizumab (EV-Pembro)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.